Try our beta test site

A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: September 7, 2011
Last updated: November 24, 2016
Last verified: November 2016

This is a study to find a maximum tolerated dose (MTD) and pharmacokinetic (PK) data for ridaforolimus given to participants between the ages of 6 and 17 years with advanced solid tumors.

Study-related visits concluded in August 2013. Participants may continue treatment until they meet discontinuation criteria or voluntarily withdraw.

Condition Intervention Phase
Solid Tumors
Drug: ridaforolimus
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Number of participants with dose limiting toxicities (DLTs) [ Time Frame: First 28-day cycle ]
  • Ridaforolimus geometric mean area under the concentration curve from hour 0 to hour 24 (AUC0-24). [ Time Frame: Cycle 1, Day 5 ]

Enrollment: 21
Study Start Date: January 2012
Estimated Study Completion Date: March 2017
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ridaforolimus Drug: ridaforolimus
Ridaforolimus supplied as 10 mg enteric-coated tablets, orally, at escalating doses starting at 22 mg/m^2 based on body surface area (BSA), for 5 consecutive days each week in consecutive 28-day cycles
Other Name: MK-8669


Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologic or cytologic diagnosis of a malignant solid tumor, including tumors of the central nervous system and lymphoma, that have progressed despite standard therapy or for which no effective standard therapy is known. Patients who have received standard therapy and continue to have biopsy-proven residual stable disease are eligible
  • Measurable or non-measurable disease
  • Must be able to swallow tablets
  • Performance Status: Lansky Play Scale ≥70 for children <10 years of age; Karnofsky score ≥70 for children ≥10 to <16 years; or Eastern Cooperative Oncology Group (ECOG) Status 0-2 for patients age 16 and older
  • Adequate organ function
  • For females of reproductive potential, a negative pregnancy test must be documented within 72 hours of receiving the first dose of study medication
  • Participants of reproductive potential must agree to use (or have their partner use) adequate contraception throughout the study, starting with Visit 1 through 30 days after the last dose of study drug

Exclusion criteria:

  • Currently receiving any other investigational agents or using any investigational devices
  • Leukemia
  • Participant previously received ridaforolimus, rapamycin, or other rapamycin analogs
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ridaforolimus
  • Persistent acute toxicity from previous therapy ≥Grade 2 (excluding alopecia, neuropathy, or hearing loss)
  • Uncontrolled intercurrent illness despite adequate therapy
  • Pregnant or breastfeeding
  • Requirement for concurrent treatment with medications that are inducers or inhibitors of cytochrome P450 (CYP3A)
  • Poorly controlled Type 1 or 2 diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT01431534     History of Changes
Other Study ID Numbers: 8669-056
Study First Received: September 7, 2011
Last Updated: November 24, 2016

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on March 27, 2017